Johnson & Johnson Presents New TECNIS PureSee IOL Clinical Data Showing Strong Contrast Sensitivity and Extended Vision Range at ASCRS 2026 Johnson & Johnson (NYSE: JNJ) has announced the presentation of new clinical and real-world data supporting the performance of…
Johnson & Johnson Reports Encouraging First-in-Human Data for Erda-iDRS (formerly TAR-210) in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Johnson & Johnson today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients…
Johnson & Johnson Secures U.S. Food and Drug Administration Approval for TECNIS PureSee Intraocular Lens, Expanding Vision Care Options for U.S. Cataract Patients Johnson & Johnson announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth…
Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium Johnson & Johnson today announced 12-month pilot-phase data from the OMNY-AF study, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation…
Johnson & Johnson Showcases New Scientific Evidence and Strengthens Leadership Through Portfolio Innovations at AF Symposium Johnson & Johnson is announcing new portfolio innovations in addition to compelling clinical evidence in atrial fibrillation (AFib) at the 31st Annual AF Symposium in Boston.…
Johnson & Johnson Launches Mobile Simulator App to Empower Breast Augmentation Patients Johnson & Johnson announced the U.S. launch of the Arbrea Breast Simulator Surgeon App for Mentor, a digital consultation tool available on tablets and smart phones that helps plastic…
The agreement aims to improve medicine affordability while supporting U.S.-based manufacturing and pharmaceutical innovation. Johnson & Johnson healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs…
Johnson & Johnson Acquires Halda Therapeutics, Gaining Innovative Platform to Transform Cancer Treatment and Advance Next-Generation Oral Therapies Johnson & Johnson today announced the successful completion of its acquisition of Halda Therapeutics OpCo, Inc. (“Halda”), a clinical-stage biotechnology company with a…
Johnson & Johnson Supports HRS Registry to Enhance Real-World Evidence for PFA ohnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced its sponsorship of a new data collection platform developed by the Heart Rhythm Society (HRS) to…
Johnson & Johnson Secures FDA Approval for TRUFILL n-BCA Liquid Embolic System to Treat Symptomatic Chronic Subdural Hematoma Johnson & Johnson MedTech, a leader in neurovascular care, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication…
Johnson & Johnson’s INLEXZO™ (Gemcitabine Intravesical System) Achieves 74% Disease-Free Survival at One Year in Patients with BCG-Unresponsive, High-Risk, Papillary-Only NMIBC Johnson & Johnson announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study…
Johnson & Johnson and Naomi Watts Urge Women Over 40 to Embrace Eye Exams as a Foundational Act of Self-Care Johnson & Johnson Vision—a global leader in eye health—has joined forces with Academy Award–nominated actress, producer, entrepreneur, and women’s health…